Karyon Bio provides AI‑driven, non‑invasive tools for early detection and management of metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form MASH. Their platform integrates multi‑omics data, imaging, electronic health records, and clinical questionnaires to generate risk scores, identify biomarkers, and deliver actionable insights for clinicians across primary‑care and hospital settings, eliminating the need for liver biopsies.
Funding
Funding not disclosed
Founders
Product
Problem
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects roughly 30% of the global population, yet early-stage detection is difficult because current diagnostics rely on invasive biopsies, expensive imaging, or laboratory tests that are not routinely performed in primary care. Delayed diagnosis leads to progression toward cirrhosis, liver failure, and cancer, increasing morbidity and healthcare costs.
Solution
Karyon Bio delivers AI‑driven, non‑invasive tools that assess fatty liver disease risk and diagnose MASLD/MASH across multiple care settings. Their platform combines multi‑omics data, imaging, electronic health records, and questionnaire inputs to generate risk scores, identify early biomarkers, and provide actionable insights for clinicians. By integrating these analyses into a unified interface, Karyon enables faster, more accurate detection and personalized management without the need for liver biopsy. The solution is scalable from primary‑care clinics to tertiary hospitals, supporting both individual patient assessment and population‑level screening.
Target Audience
Primary customers are hepatologists, gastroenterologists, and primary‑care physicians who need rapid, non‑invasive liver disease screening, as well as research institutions and hospitals seeking AI‑enabled diagnostic and biomarker discovery tools for MASLD/MASH.
Features
- LivIQ: an agentic AI system that unifies diagnostics, risk prediction, and research insights for liver disease in a single workflow
- LivRisk: a multi‑modal platform that fuses genomics, imaging, EHR, and clinical data to power AI‑based diagnosis and biomarker discovery
- LivRNA+: automated mining of public RNA‑seq datasets to surface early‑stage liver disease biomarkers
- Liv3T: tiered risk assessment using anthropometric data, vital signs plus serum markers, and comprehensive liver function tests
- LivAid: AI‑enhanced knowledge‑graph and language model that validates liver biomarkers and provides expert information on MASLD/MASH
- Med DX: AI diagnostic engine that processes liver imaging (CT, ultrasound, histopathology) to improve accuracy and streamline clinician workflow